Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03577197

Southeast Netherlands Advanced Metastatic Breast Cancer Registry

Southeast Netherlands Advanced Breast Cancer Registry

Status
Recruiting
Phase
Study type
Observational
Enrollment
7,000 (estimated)
Sponsor
Academisch Ziekenhuis Maastricht · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The Southeast Netherlands Advanced Breast Cancer (SONABRE) Registry is a real life multi-center study. The registry aims to include all patients diagnosed with advanced breast cancer as of 2007 in 11 hospitals in the Netherlands. Data on patient, tumor and treatment characteristics are collected retrospectively from electronic medical files by trained registry clerks.

Detailed description

This SONABRE registry is an ongoing observational cohort study aiming at the inclusion of all patients aged ≥18 years and diagnosed with advanced breast cancer since 2007 in 11 hospitals in the Southeast of the Netherlands. Patients with de novo or recurrent advanced breast cancer were identified from the hospital-based management information systems. Specially trained registration clerks retrospectively collected data from the medical files of the patients based on extensive medical chart review. Information was collected about patient and tumour characteristics, type of treatment (surgery, radiotherapy and systemic treatment, both neo-adjuvant, adjuvant and palliative), palliative treatment changes due to adverse events, hospitalization, comorbidities and outcomes (progression and death). The SONABRE Registry has already been effectively used to perform real-life studies on the use, safety and (cost-)effectiveness of various systemic treatments used in patients diagnosed with advanced breast cancer.

Conditions

Timeline

Start date
2007-01-01
Primary completion
2027-12-31
Completion
2027-12-31
First posted
2018-07-05
Last updated
2024-07-23

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT03577197. Inclusion in this directory is not an endorsement.